We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)

This study is currently recruiting participants.
Verified October 2017 by Amgen
Sponsor:
ClinicalTrials.gov Identifier:
NCT02929329
First Posted: October 11, 2016
Last Update Posted: October 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Cytokinetics
Servier
Information provided by (Responsible Party):
Amgen
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 27, 2021
  Estimated Primary Completion Date: January 27, 2021 (Final data collection date for primary outcome measure)